PharmaResearch(214450) said on the 4th that it launched "Gyner," its first entry in the obstetrics and gynecology market, at the Korean Society for Sexual Medicine and Women's Health academic conference.
The company took part in the "Korean Society for Sexual Medicine and Women's Health summer conference," held at the Plenty Convention of Seoul St. Mary's Hospital on the 26th, and began promotions for "Gyner."
The Korean Society for Sexual Medicine and Women's Health is an academic organization that shares the latest research and clinical experience to improve women's quality of life and advance the field of women's sexual medicine. About 200 gynecologists attended the conference.
PharmaResearch introduced the product features and potential clinical applications of "Gyner," a class II adhesive transparent wound dressing that applies its proprietary patented ingredient, DOT® PN.
"Gyner" is an adhesive, transparent wound dressing applied to minor bleeding or low-exudate wounds in sensitive areas such as the female perineum to prevent skin damage. It helps heal perineal wounds caused by vaginal dryness and protects the skin from external irritation for hygienic care.
PharmaResearch plans to use this launch to expand academic exchanges with gynecology medical staff and to strengthen its product lineup in the gynecology field based on the DOT® PN ingredient.
A PharmaResearch official said, "We are pursuing portfolio expansion into the obstetrics and gynecology field based on the DOT® PN ingredient," adding, "Starting with the launch of Gyner, we will gradually expand related product lines and continue to accumulate clinical data and market insights through academic exchanges with key medical staff."
Meanwhile, PharmaResearch develops and sells pharmaceuticals, medical devices, cosmetics, and health functional foods using DOT® PDRN and DOT® PN substances based on regenerative medicine technology. Its flagship brands include Rejuran, Rejuviel, Rejuran Cosmetic, Reintok, Evercl, Rejuderma, and Rejuvinex.